The extreme chemical diversity of CNH molecules is at the same time very important (central in organic chemistry) and difficult to rationalize in the sense that some molecules are abundant and easy to synthesize, while others are rare and difficult to make. Using the recently developed criteria of molecular "magicity", combined with evolutionary structure prediction and quantum-chemical calculations, we study these molecules in a wide range of compositions (0 ≤ ≤ 13, 0 ≤ ≤ 4, and 0 ≤ ≤ 14). "Magic" molecules are defined as those that are lower in energy than any isochemical mixture of molecules with the nearest compositions. The predicted "magic" molecules are in good agreement with compounds found in versatile environments (interstellar and circumstellar media, Titan's lower atmosphere, and crude oil fractions) and in experimental chemistry. This work shows the predictive power of our approach, capable of predicting and explaining stable molecules in complex systems.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jpclett.3c01753DOI Listing

Publication Analysis

Top Keywords

≤ ≤
20
molecules
8
"magic" molecules
8
6
prediction rationalization
4
rationalization abundant
4
abundant c-n-h
4
c-n-h molecules
4
molecules environments
4
environments extreme
4

Similar Publications

Reply to 'The need for a better classification system for gastric neoplasms'.

Nat Rev Dis Primers

January 2025

Department of Medical and Surgical Sciences, Alma Mater Studiorum - Universtà di Bologna, Bologna, Italy.

View Article and Find Full Text PDF

Objective: As aneurysmal disease is progressive, proximal disease progression and para-anastomotic aneurysms are complications experienced after open infrarenal abdominal aortic aneurysm repair (AAA). As such, fenestrated or branched endovascular repair (F/BEVAR) may be indicated in these patients. Data describing fenestrated endovascular aneurysm repair after prior open repair are limited to institutional databases.

View Article and Find Full Text PDF

Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events.

Eur J Cancer

January 2025

Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany; Experimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany. Electronic address:

Background: Despite remarkable clinical efficacy, little is known about the system-wide immunological alterations provoked by PD1 blockade. Dynamics of quantitative immune composition and functional repertoire during PD1 blockade could delineate cohort-specific patterns of treatment response and therapy-induced toxicity.

Methods: We longitudinally assessed therapy-induced effects on the immune system in fresh whole blood using flow cytometry-based cell quantifications, accompanied by analyses of effector properties of all major immune populations upon cell-type specific stimulations.

View Article and Find Full Text PDF

Purpose: This retrospective analysis evaluates baseline F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with [Lu]Lu-PSMA-I&T.

Methods: A total of 188 mCRPC patients with baseline F-flotufolastat PET scans were included. Tumor lesions were semiautomatically delineated, with imaging parameters including volume-based and standardized uptake value (SUV)-based metrics.

View Article and Find Full Text PDF

This review describes mass spectrometry (MS)-based approaches for the absolute quantification of therapeutic monoclonal antibodies (mAbs), focusing on technical challenges in sample treatment and calibration. Therapeutic mAbs are crucial for treating cancer and inflammatory, infectious, and autoimmune diseases. We trace their development from hybridoma technology and the first murine mAbs in 1975 to today's chimeric and fully human mAbs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!